PMC:7600245 / 23590-24063
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T87 | 96-104 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T88 | 105-114 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T89 | 415-430 | Disease | denotes | virus infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T90 | 421-430 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T221 | 21-26 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T222 | 262-263 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T223 | 312-313 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T224 | 353-354 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T225 | 382-390 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
| T226 | 415-420 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T325 | 21-26 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T326 | 138-149 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T327 | 322-327 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T328 | 341-351 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T329 | 365-374 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T44 | 382-397 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T12 | 105-114 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T173 | 0-473 | Sentence | denotes | Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 653 | 138-149 | Chemical | denotes | favipiravir | MESH:C462182 |
| 654 | 341-351 | Chemical | denotes | umifenovir | MESH:C086979 |
| 663 | 96-114 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 664 | 415-430 | Disease | denotes | virus infection | MESH:D001102 |